A phenotype-based model for rational selection of novel targeted therapies in treating aggressive breast cancer

ABSTRACT: Treating unselected cancer patients with new drugs dilutes proof of efficacy when only a fraction of patients respond to therapy. We conducted a meta-analysis on eight primary breast cancer microarray datasets representing diverse breast cancer phenotypes. We present a high-throughput protocol which incorporates drug sensitivity signatures to guide preclinical testing for effective therapeutic agents. Specifically, we focus on drug classes currently undergoing early phase clinical testing. Our genomic and experimental results suggest that the majority of basal-like breast cancers should respond to inhibitors of the phosphatidylinositol-3-kinase pathway, and that a relatively low toxicity histone deacetylase inhibitor, valproic acid, may target aggressive breast cancers. For a subset of dru

ORGANISM(S): Homo sapiens

SUBMITTER: Gustafson Adam 

PROVIDER: S-ECPF-GEOD-18331 | biostudies-other |

REPOSITORIES: biostudies-other